



## Clinical trial results:

### An open monocentric pilot study to investigate the potential of imiquimod 5% cream to detect residual and to prevent recurrence of lentigo maligna after surgical excision

#### Summary

EudraCT number	2010-019422-13
Trial protocol	AT
Global end of trial date	02 November 2022

#### Results information

Result version number	v1 (current)
This version publication date	21 February 2024
First version publication date	21 February 2024

#### Trial information

##### Trial identification

Sponsor protocol code	2010-1
-----------------------	--------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Medical University of Graz
Sponsor organisation address	Neue Stiftingtalstraße 6, Graz, Austria, 8010
Public contact	Principal investigator Department of Dermatology and Venereology, Medical University of Graz  Department of Dermatology and Venereology, peter.wolf@medunigraz.at
Scientific contact	Principal investigator Department of Dermatology and Venereology, Medical University of Graz  Department of Dermatology and Venereology, peter.wolf@medunigraz.at

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

### Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 November 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	02 November 2022
Global end of trial reached?	Yes
Global end of trial date	02 November 2022
Was the trial ended prematurely?	No

Notes:

### General information about the trial

Main objective of the trial:

The primary objective of the study is to investigate the potential of Imiquimod 5% cream to eliminate possible subclinical lesions of lentigo maligna (LM) that resides after surgical excision by determining the long-term recurrence rates.

Protection of trial subjects:

The study was conducted according to Good Clinical Practice standards and according to applicable laws and regulations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	17 March 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	5 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

### Population of trial subjects

#### Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 60
Worldwide total number of subjects	60
EEA total number of subjects	60

Notes:

#### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	23
From 65 to 84 years	35
85 years and over	2

## Subject disposition

### Recruitment

Recruitment details:

The recruitment period lasted from 2011 to 2016.

### Pre-assignment

Screening details:

A total of 60 patients were recruited.

7 patients didn't start study therapy due to withdrawal of consent (4x), or protocol deviations regarding the timepoint of therapy initiation (2x). One patient was a screening failure

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Imiquimod
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Imiquimod
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Aldara® cream was applied post-surgery to the study treatment area (STA), defined as the area within a range of 5cm of treatment margins to each side of the original scar of the excision. Time period between removal of stitches and first administration of Aldara® has not been shorter than 4 weeks. At first Aldara® was applied 3x/week on the scar and on the perilesional area (5cm). After two weeks of treatment the inflammation response was assessed. If there was no inflammation detectable in the STA, application was extended to 5x/week. After four weeks of treatment the inflammation response was assessed again. If there was still no inflammation detectable, application was extended to daily use. The total treatment cycle was up to 12 weeks, if tolerated by the patient.

<b>Number of subjects in period 1<sup>[1]</sup></b>	Imiquimod
Started	53
Completed	49
Not completed	4
Lost to follow-up	4

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 60 patients signed Informed Consent and were therefore considered "enrolled".

7 patients never started study treatment due to withdrawal of consent (4x), protocol deviations (2x) or screening failure (1x).

## Baseline characteristics

### Reporting groups

Reporting group title	Overall trial
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	53	53	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
arithmetic mean	64.5		
full range (min-max)	33 to 83	-	
Gender categorical			
Units: Subjects			
Female	22	22	
Male	31	31	

## End points

---

### End points reporting groups

Reporting group title	Imiquimod
Reporting group description: -	

---

### Primary: Percentage of patients having a relapse

End point title	Percentage of patients having a relapse <sup>[1]</sup>
End point description:	

End point type	Primary
----------------	---------

End point timeframe:

5 years

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistical analysis was performed

End point values	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	49			
Units: percent				
number (not applicable)	8.2			

---

### Statistical analyses

No statistical analyses for this end point

---

### Primary: Percentage of Lentigo Maligna patients with a relapse

End point title	Percentage of Lentigo Maligna patients with a relapse <sup>[2]</sup>
-----------------	--

End point description:

Lentigo Maligna patients with complete excision and uncertain completed excision

End point type	Primary
----------------	---------

End point timeframe:

5 years

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was performed

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	28			
Units: percent				
number (not applicable)	0			

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Lentigo Maligna Melanoma patients with a relapse

End point title	Percentage of Lentigo Maligna Melanoma patients with a relapse <sup>[3]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

5 years

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was performed

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: percent				
number (not applicable)	19			

### Statistical analyses

No statistical analyses for this end point

### Primary: Relapse free time after surgery plus application of Imiquimod

End point title	Relapse free time after surgery plus application of Imiquimod <sup>[4]</sup>
-----------------	--

End point description:

Relapse free time after surgery followed by application of imiquimod, for patients having a recurrence of LM/LMM in the Study treatment area.

End point type	Primary
----------------	---------

End point timeframe:

5 years

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was performed

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	49			
Units: Months				
First patient with a relapse	2			
Second patient with a relapse	5			
Third patient with a relapse	28			
Fourth patient with a relapse	36			

## Statistical analyses

No statistical analyses for this end point

### Primary: Recurrence free rate

End point title	Recurrence free rate <sup>[5]</sup>
-----------------	-------------------------------------

End point description:

End point type	Primary
----------------	---------

End point timeframe:

5 years

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was performed

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	32			
Units: percent				
number (not applicable)	91.84			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect: Erythema, week 2

End point title	Side effect: Erythema, week 2
-----------------	-------------------------------

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.

Side effects were documented during the study visits.

End point type	Secondary
----------------	-----------

End point timeframe:

2 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	51			
Units: Number of patients				
Severity index 0, men	12			
Severity index 0, women	14			
Severity index 1, men	6			
Severity index 1, women	7			
Severity index 2, men	8			
Severity index 2, women	4			
Severity index 3, men	0			
Severity index 3, women	0			
Severity index 4, men	0			
Severity index 4, women	0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, oedema, week 2

End point title	Side effect, oedema, week 2
End point description:	Severity index ranges from 0 to 4, higher values indicating more severity. Side effects were documented during the study visits.
End point type	Secondary
End point timeframe:	2 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	51			
Units: Number of patients				
Severity index 0, men	19			
Severity index 0, women	17			
Severity index 1, men	5			
Severity index 1, women	8			
Severity index 2, men	2			
Severity index 2, women	0			
Severity index 3, men	0			
Severity index 3, women	0			
Severity index 4, men	0			
Severity index 4, women	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, Blister, week 2

End point title | Side effect, Blister, week 2

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.  
Side effects were documented during the study visits.

End point type | Secondary

End point timeframe:

2 weeks

End point values	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	51			
Units: Number of patients				
Severity index 0, men	25			
Severity index 0, women	23			
Severity index 1, men	1			
Severity index 1, women	1			
Severity index 2, men	0			
Severity index 2, women	1			
Severity index 3, men	0			
Severity index 3, women	0			
Severity index 4, men	0			
Severity index 4, women	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, erosion, week 2

End point title | Side effect, erosion, week 2

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.  
Side effects were documented during the study visits.

End point type | Secondary

End point timeframe:

2 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	51			
Units: Number of patients				
Severity index 0, men	20			
Severity index 0, women	18			
Severity index 1, men	4			
Severity index 1, women	5			
Severity index 2, men	2			
Severity index 2, women	2			
Severity index 3, men	0			
Severity index 3, women	0			
Severity index 4, men	0			
Severity index 4, women	0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect: Encrustation, week 2

End point title	Side effect: Encrustation, week 2
End point description:	Severity index ranges from 0 to 4, higher values indicating more severity. Side effects were documented during the study visits.
End point type	Secondary
End point timeframe:	2 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	51			
Units: Number of patients				
Severity index 0, men	23			
Severity index 0, women	20			
Severity index 1, men	3			
Severity index 1, women	4			
Severity index 2, men	0			
Severity index 2, women	1			
Severity index 3, men	0			
Severity index 3, women	0			
Severity index 4, men	0			
Severity index 4, women	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect; erythema, week 4

End point title | Side effect; erythema, week 4

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.  
Side effects were documented during the study visits.

End point type | Secondary

End point timeframe:

4 weeks

End point values	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Number of patients				
Severity index 0, men	8			
Severity index 0, women	8			
Severity index 1, men	5			
Severity index 1, women	5			
Severity index 2, men	7			
Severity index 2, women	6			
Severity index 3, men	2			
Severity index 3, women	2			
Severity index 4, men	0			
Severity index 4, women	1			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect: Oedema, week 4

End point title | Side effect: Oedema, week 4

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.  
Side effects were documented during the study visits.

End point type | Secondary

End point timeframe:

4 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Number of patients				
Severity index 0, men	12			
Severity index 0, women	14			
Severity index 1, men	7			
Severity index 1, women	3			
Severity index 2, men	1			
Severity index 2, women	4			
Severity index 3, men	1			
Severity index 3, women	0			
Severity index 4, men	1			
Severity index 4, women	1			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, blister, week 4

End point title	Side effect, blister, week 4
End point description:	Severity index ranges from 0 to 4, higher values indicating more severity. Side effects were documented during the study visits.
End point type	Secondary
End point timeframe:	4 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Number of patients				
Severity index 0, men	18			
Severity index 0, women	16			
Severity index 1, men	3			
Severity index 1, women	3			
Severity index 2, men	0			
Severity index 2, women	2			
Severity index 3, men	1			
Severity index 3, women	0			
Severity index 4, men	0			
Severity index 4, women	1			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect: erosion, week 4

End point title | Side effect: erosion, week 4

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.  
Side effects were documented during the study visits.

End point type | Secondary

End point timeframe:

4 weeks

End point values	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Number of patients				
Severity index 0, men	14			
Severity index 0, women	14			
Severity index 1, men	5			
Severity index 1, women	3			
Severity index 2, men	2			
Severity index 2, women	2			
Severity index 3, men	1			
Severity index 3, women	1			
Severity index 4, men	0			
Severity index 4, women	2			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, encrustation, week 4

End point title | Side effect, encrustation, week 4

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.  
Side effects were documented during the study visits.

End point type | Secondary

End point timeframe:

4 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Number of patients				
Severity index 0, men	15			
Severity index 0, women	12			
Severity index 1, men	3			
Severity index 1, women	5			
Severity index 2, men	4			
Severity index 2, women	3			
Severity index 3, men	0			
Severity index 3, women	1			
Severity index 4, men	0			
Severity index 4, women	1			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, erythema, week 8

End point title	Side effect, erythema, week 8
End point description:	Severity index ranges from 0 to 4, higher values indicating more severity. Side effects were documented during the study visits.
End point type	Secondary
End point timeframe:	8 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	45			
Units: Number of patients				
Severity index 0, men	5			
Severity index 0, women	9			
Severity index 1, men	5			
Severity index 1, women	4			
Severity index 2, men	10			
Severity index 2, women	6			
Severity index 3, men	3			
Severity index 3, women	3			
Severity index 4, men	0			
Severity index 4, women	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect: Oedema, week 8

End point title | Side effect: Oedema, week 8

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.  
Side effects were documented during the study visits.

End point type | Secondary

End point timeframe:

8 weeks

End point values	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	45			
Units: Number of patients				
Severity index 0, men	12			
Severity index 0, women	13			
Severity index 1, men	5			
Severity index 1, women	6			
Severity index 2, men	4			
Severity index 2, women	3			
Severity index 3, men	2			
Severity index 3, women	0			
Severity index 4, men	0			
Severity index 4, women	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, Blister, week 8

End point title | Side effect, Blister, week 8

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.  
Side effects were documented during the study visits.

End point type | Secondary

End point timeframe:

8 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	45			
Units: Number of patients				
Severity index 0, men	18			
Severity index 0, women	20			
Severity index 1, men	3			
Severity index 1, women	1			
Severity index 2, men	1			
Severity index 2, women	1			
Severity index 3, men	1			
Severity index 3, women	0			
Severity index 4, men	0			
Severity index 4, women	0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, Erosion, week 8

End point title	Side effect, Erosion, week 8
End point description:	Severity index ranges from 0 to 4, higher values indicating more severity. Side effects were documented during the study visits.
End point type	Secondary
End point timeframe:	8 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	45			
Units: Number of patients				
Severity index 0, men	11			
Severity index 0, women	16			
Severity index 1, men	6			
Severity index 1, women	1			
Severity index 2, men	3			
Severity index 2, women	3			
Severity index 3, men	3			
Severity index 3, women	2			
Severity index 4, men	0			
Severity index 4, women	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, encrustation, week 8

End point title | Side effect, encrustation, week 8

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.  
Side effects were documented during the study visits.

End point type | Secondary

End point timeframe:

8 weeks

End point values	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	45			
Units: Number of patients				
Severity index 0, men	11			
Severity index 0, women	15			
Severity index 1, men	4			
Severity index 1, women	2			
Severity index 2, men	4			
Severity index 2, women	3			
Severity index 3, men	4			
Severity index 3, women	1			
Severity index 4, men	0			
Severity index 4, women	1			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, Erythema, week 12

End point title | Side effect, Erythema, week 12

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.  
Side effects were documented during the study visits.

End point type | Secondary

End point timeframe:

12 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Number of patients				
Severity index 0, men	5			
Severity index 0, women	7			
Severity index 1, men	10			
Severity index 1, women	5			
Severity index 2, men	6			
Severity index 2, women	6			
Severity index 3, men	4			
Severity index 3, women	1			
Severity index 4, men	0			
Severity index 4, women	0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, Oedema, week 12

End point title	Side effect, Oedema, week 12
End point description:	Severity index ranges from 0 to 4, higher values indicating more severity. Side effects were documented during the study visits.
End point type	Secondary
End point timeframe:	12 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Number of patients				
Severity index 0, men	17			
Severity index 0, women	14			
Severity index 1, men	2			
Severity index 1, women	4			
Severity index 2, men	1			
Severity index 2, women	1			
Severity index 3, men	5			
Severity index 3, women	0			
Severity index 4, men	0			
Severity index 4, women	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, Blister, week 12

End point title | Side effect, Blister, week 12

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.  
Side effects were documented during the study visits.

End point type | Secondary

End point timeframe:

12 weeks

End point values	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Number of patients				
Severity index 0, men	21			
Severity index 0, women	19			
Severity index 1, men	2			
Severity index 1, women	0			
Severity index 2, men	1			
Severity index 2, women	0			
Severity index 3, men	1			
Severity index 3, women	0			
Severity index 4, men	0			
Severity index 4, women	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, Erosion, week 12

End point title | Side effect, Erosion, week 12

End point description:

Severity index ranges from 0 to 4, higher values indicating more severity.  
Side effects were documented during the study visits.

End point type | Secondary

End point timeframe:

12 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Number of patients				
Severity index 0, men	16			
Severity index 0, women	14			
Severity index 1, men	5			
Severity index 1, women	3			
Severity index 2, men	1			
Severity index 2, women	2			
Severity index 3, men	3			
Severity index 3, women	0			
Severity index 4, men	0			
Severity index 4, women	0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Side effect, encrustation, week 12

End point title	Side effect, encrustation, week 12
End point description:	Severity index ranges from 0 to 4, higher values indicating more severity. Side effects were documented during the study visits.
End point type	Secondary
End point timeframe:	12 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	44			
Units: Number of patients				
Severity index 0, men	13			
Severity index 0, women	14			
Severity index 1, men	5			
Severity index 1, women	4			
Severity index 2, men	4			
Severity index 2, women	1			
Severity index 3, men	2			
Severity index 3, women	0			
Severity index 4, men	1			
Severity index 4, women	0			

## Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Frequency of applications of Imiquimod, Week 1-2

End point title | Frequency of applications of Imiquimod, Week 1-2

End point description:

End point type | Other pre-specified

End point timeframe:

2 weeks

End point values	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	53			
Units: percent				
number (not applicable)				
0-1 applications, week 1-2, men	4			
0-1 applications, week 1-2, women	0			
2 applications, week 1-2, men	0			
2 applications, week 1-2, women	0			
3 applications, week 1-2, men	0			
3 applications, week 1-2, women	0			
4 applications, week 1-2, men	4			
4 applications, week 1-2, women	14			
5 applications, week 1-2, men	7			
5 applications, week 1-2, women	0			
≥ 6 applications, week 1-2, men	85			
≥ 6 applications, week 1-2, women	86			

## Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Frequency of applications of Imiquimod, Week 3-4

End point title | Frequency of applications of Imiquimod, Week 3-4

End point description:

End point type | Other pre-specified

End point timeframe:

2 weeks

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	53			
Units: percent				
number (not applicable)				
0-1 applications, men	0			
0-1 applications, women	10			
2-3 applications, men	4			
2-3 applications, women	0			
4-5 applications, men	4			
4-5 applications, women	10			
6-7 applications, men	15			
6-7 applications, women	5			
8-9 applications, men	12			
8-9 applications, women	10			
10 applications, men	65			
10 applications, women	65			

### Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Frequency of applications of Imiquimod, Week 5-8

End point title	Frequency of applications of Imiquimod, Week 5-8
End point description:	
End point type	Other pre-specified
End point timeframe:	
3 weeks	

<b>End point values</b>	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	53			
Units: percent				
number (not applicable)				
0-5 applications, men	10			
0-5 applications, women	17			
6-11 applications, men	10			
6-11 applications, women	9			
12-17 applications, men	23			
12-17 applications, women	31			
18-22 applications, men	17			
18-22 applications, women	13			
23-27 applications, men	3			
23-27 applications, women	4			
28 applications, men	37			

28 applications, women	26			
------------------------	----	--	--	--

### Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Frequency of applications of Imiquimod, Week 9-12

End point title	Frequency of applications of Imiquimod, Week 9-12
-----------------	---

End point description:

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

3 weeks

End point values	Imiquimod			
Subject group type	Reporting group			
Number of subjects analysed	53			
Units: percent				
number (not applicable)				
0-5 applications, men	7			
0-5 applications, women	23			
6-11 applications, men	18			
6-11 applications, women	17			
12-17 applications, men	32			
12-17 applications, women	13			
18-22 applications, men	18			
18-22 applications, women	17			
23-27 applications, men	7			
23-27 applications, women	4			
28 applications, men	18			
28 applications, women	26			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

5 years

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.1
--------------------	------

### Reporting groups

Reporting group title	Imiquimod
-----------------------	-----------

Reporting group description: -

Serious adverse events	Imiquimod		
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 53 (30.19%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lipoma			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Adenocarcinoma of colon	Additional description: Diagnosis of event and hospitalisation for treatment were documented as SAE, respectively		
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neoplasm recurrence	Additional description: Recurrence of melanoma		
subjects affected / exposed	4 / 53 (7.55%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Investigations			
Angiography	Additional description: Hospitalisation due to Coronary angiography		
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Skin and subcutaneous tissue therapeutic procedures	Additional description: Excision of basal cell carcinoma and re-excision of recurring melanoma		
subjects affected / exposed	3 / 53 (5.66%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Subdural haematoma			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Basal cell carcinoma			
subjects affected / exposed	3 / 53 (5.66%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma			
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Purpura	Additional description: posttraumatic purpura		
subjects affected / exposed	1 / 53 (1.89%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Imiquimod		
Total subjects affected by non-serious adverse events subjects affected / exposed	48 / 53 (90.57%)		
Nervous system disorders Headache subjects affected / exposed occurrences (all)	3 / 53 (5.66%) 3		
General disorders and administration site conditions Influenza like illness subjects affected / exposed occurrences (all)	3 / 53 (5.66%) 3		
Skin and subcutaneous tissue disorders Skin erosion subjects affected / exposed occurrences (all)  Erythema subjects affected / exposed occurrences (all)  Oedema subjects affected / exposed occurrences (all)  Blister subjects affected / exposed occurrences (all)  crust subjects affected / exposed occurrences (all)	33 / 53 (62.26%) 61  44 / 53 (83.02%) 114  34 / 53 (64.15%) 66  18 / 53 (33.96%) 24  33 / 53 (62.26%) 59		
Infections and infestations Oral herpes subjects affected / exposed occurrences (all)	1 / 53 (1.89%) 3		

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported